Together, our combined in vivo and in vitro data suggest that the levels of both Sema3A and its cobinding receptor, NRP1, are presymptomatically increased in several ALS models as well as in sALS patients. This evidence concerns the gene NRP1 and amyotrophic lateral sclerosis.